Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805607 · ClinicalTrials.gov registry record · Phase 4
IV Ketorolac on Platelet Function Post-Cesarean Delivery
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03805607 is a Phase 4 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT03805607, a Phase 4 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. The investigators plan to use Platelet Aggregometry and Thromboelastography (TEG) to evaluate the effect of ketorolac on platelets.
Interventions
- DRUG Placebos
- DRUG Ketorolac Tromethamine 30 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03805607
The ClinicalTrials.gov registry entry for NCT03805607 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03805607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03805607 about?
NCT03805607 is a clinical study titled "IV Ketorolac on Platelet Function Post-Cesarean Delivery". Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of plat...
What is the current status of trial NCT03805607?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2021-01-18. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT03805607?
The interventions under investigation include: Placebos (DRUG), Ketorolac Tromethamine 30 MG/ML (DRUG).
Who is sponsoring clinical trial NCT03805607?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.